Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, comparative, multi-center study of the safety and efficacy of TG 873870 [Nemonoxacin; Taigen Biotechnology] versus levofloxacin in adult patients with community-acquired pneumonia CAP

Next Previous
X
Search
Trial Profile

A randomized, double-blind, comparative, multi-center study of the safety and efficacy of TG 873870 [Nemonoxacin; Taigen Biotechnology] versus levofloxacin in adult patients with community-acquired pneumonia CAP

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemonoxacin (Primary) ; Levofloxacin
  • Indications Chlamydial infections; Community-acquired pneumonia; Haemophilus infections; Mycoplasma infections; Pneumococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TaiGen Biotechnology

    • Most Recent Events

    • 28 Oct 2008 Results were published at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - A Joint Meeting.
    • 20 Oct 2008 Primary endpoint 'Clinical cure rate' has been met, according to a TaiGen media release.
    • 20 Oct 2008 Top-line results will be presented at ICAAC/IDSA, according to a TaiGen media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top